Theriva Biologics, Inc. fell 11.8% on Tuesday, November 10, 2026, on 562,100 shares. No headline about TOVX came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Theriva Biologics, Inc. (TOVX:NYSEMKT) closed at $0.144 on November 13, 2026, down 9.94% on the day. The stock trades 70.6% below its 52-week high of $0.490 and 2.9% above its 52-week low of $0.140. Over the past year, it lost 40.0%. Theriva Biologics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, TOVX closed higher on 71 days (28%). Its best day was April 20, 2026 (+57.69%) and its worst was December 1, 2025 (-18.52%). The stock moved 10% or more in a single session 26 times. It opened at least 5% above the previous day's high 8 times.
Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria.
Find more stocks like TOVX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.